Brokerages forecast that Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) will report earnings of ($0.50) per share for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Cyclacel Pharmaceuticals’ earnings. Cyclacel Pharmaceuticals reported earnings of ($1.48) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 66.2%. The company is expected to report its next earnings results on Tuesday, May 11th.
On average, analysts expect that Cyclacel Pharmaceuticals will report full year earnings of ($2.23) per share for the current year, with EPS estimates ranging from ($2.35) to ($2.11). For the next year, analysts expect that the firm will report earnings of ($2.46) per share, with EPS estimates ranging from ($2.53) to ($2.39). Zacks’ EPS calculations are an average based on a survey of analysts that cover Cyclacel Pharmaceuticals.
Cyclacel Pharmaceuticals (NASDAQ:CYCC) last issued its quarterly earnings data on Thursday, February 25th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.51) by ($0.83).
Shares of NASDAQ CYCC traded up $0.14 during midday trading on Friday, hitting $7.29. 747 shares of the company traded hands, compared to its average volume of 692,148. Cyclacel Pharmaceuticals has a 12-month low of $3.12 and a 12-month high of $19.25. The firm has a market cap of $51.79 million, a P/E ratio of -1.37 and a beta of 1.34. The stock has a 50-day moving average price of $7.50 and a 200 day moving average price of $5.93.
A number of large investors have recently bought and sold shares of the stock. Virtu Financial LLC bought a new position in shares of Cyclacel Pharmaceuticals during the fourth quarter valued at approximately $80,000. Raymond James Financial Services Advisors Inc. increased its position in Cyclacel Pharmaceuticals by 48.8% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 45,756 shares of the biotechnology company’s stock valued at $167,000 after buying an additional 15,000 shares in the last quarter. Acuta Capital Partners LLC purchased a new position in Cyclacel Pharmaceuticals during the fourth quarter valued at $1,172,000. Ikarian Capital LLC bought a new stake in Cyclacel Pharmaceuticals in the fourth quarter worth $3,057,000. Finally, Pura Vida Investments LLC purchased a new stake in shares of Cyclacel Pharmaceuticals in the fourth quarter worth $3,710,000. 4.20% of the stock is currently owned by institutional investors and hedge funds.
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias.
Read More: Day Trading – Risk Worth the Reward?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.